Q1 2024 Earnings Summary
- Fortrea reported a strong win rate in Q1 2024, the best since its spin-off, indicating robust demand and successful client engagements. Despite a few rescheduled and canceled projects, the company noted strong double-digit growth in the dollar value of its pipeline, which positions it well for future bookings.
- The company is being viewed as a peer by large pharmaceutical customers, opening doors to larger contracts and strategic partnerships. Fortrea is at the table in key partnering discussions and is competing for both full-service and hybrid Functional Service Provider (FSP) contracts, enhancing its competitive position.
- Fortrea expects to improve margins through cost actions and operating leverage, targeting adjusted EBITDA margins of approximately 13% in 2025, consistent with 2022 levels. This improvement is expected from SG&A reductions, productivity enhancements, and modest revenue growth, allowing for strong revenue drop-through without significant additional resources.
- Fortrea expects negative free cash flow for the full year 2024 due to significant one-time costs related to the spin-off, and plans to use its revolver or accounts receivable facility to cover the shortfall, potentially increasing its debt burden.
- The company lowered its revenue guidance for 2024, now expecting overall revenue growth to be flat versus 2023, reflecting lower study start-ups and a lower-than-anticipated book-to-bill ratio in the first quarter, indicating challenges in driving top-line growth.
- Fortrea adjusted its credit agreements to loosen financial covenants and is selling receivables to reduce interest expenses, which may suggest financial strain and potential liquidity concerns.
-
Margin Outlook
Q: How will you achieve 13% margin by year-end?
A: We expect to reach 13% EBITDA margin by year-end, primarily through gross margin improvements from modest revenue growth in the second half. Since we won't need to add resources to support this growth, most of the revenue will drop through to margins. Only about a quarter of the improvement will come from SG&A cost actions, as we can't significantly reduce SG&A until we fully exit our TSAs. , -
Demand Outlook
Q: What is the current demand environment and pipeline growth?
A: Our pipeline has strong double-digit growth in dollar value, indicating solid demand. We're receiving more opportunities and are being viewed as a peer by large customers. However, as a smaller company, a couple of large deals can significantly influence our results. , -
Cancellations Impact
Q: How did cancellations affect your results?
A: We experienced a fairly large cancellation at the end of the quarter, which, along with a sizable opportunity being rescheduled, caused us to miss our book-to-bill target by 0.1 point. Excluding that, cancellations were at normal levels during the quarter. , -
Burn Rate Timing
Q: Can you detail the burn rate assumptions through the year?
A: Our burn rate is slower than traditional metrics suggest due to our mix of oncology and biotech projects—about 50% biotech—which often involve more protocol changes and startup activities. This is a timing issue, not cancellations, and we expect momentum to pick up later next year, more so into 2025. -
Free Cash Flow Expectations
Q: Will free cash flow be positive or negative this year?
A: We expect free cash flow to be slightly negative for the full year, improving as we progress and turning positive by year-end. We'll use our revolver or AR facility to support any shortfall; this is largely due to significant one-time costs incurred related to the spin-off. -
Capital Structure Update
Q: Why did you amend your maintenance covenants?
A: We amended our maintenance covenants out of caution, recognizing that trailing 12-month measures are calculated post-divestiture. The amendment was mainly due to accounting impacts from the asset sale. -
Pricing Dynamics
Q: Are customers becoming more price-sensitive, and is competition increasing?
A: Customers have always been price-sensitive; nothing particularly new there. However, the largest FSP contracts are becoming highly competitive. We're monitoring private CROs to ensure disciplined pricing remains in the industry. -
Business Mix Focus
Q: Are you prioritizing biotech over large pharma?
A: We view our business as a 50-50 split between biotech and large pharma. We continue to make progress with large pharma while also focusing on biotech, which drives much of the innovative drug development. There's no change in our prioritization. ,
Research analysts covering Fortrea Holdings.